塞利尼索联合维奈克拉、阿扎胞苷方案诱导治疗复发难治急性髓系白血病的疗效及安全性观察

The clinical safety and efficacy of selinexor combined with venetoclax and azactitidine induction therapy in relapsed and refractory acute myeloid leukemia

为探讨塞利尼索联合维奈克拉(VEN)、阿扎胞苷(AZA)在复发难治急性髓系白血病(R/R AML)患者中的疗效及安全性,纳入2022年5月至2023年5月在郑州大学附属肿瘤医院接受塞利尼索联合VEN、AZA方案的12例R/R AML患者,对其临床资料进行回顾性分析。12例患者中,完全缓解(CR)5例(41.7%),CR伴血液学不完全恢复1例(8.3%),部分缓解5例(41.7%)。达CR中位时间28(16~59)d。中位无病生存期为61(15~300)d。该方案的主要不良反应为血液学不良反应,无化疗相关死亡。塞利尼索联合VEN、AZA方案是治疗R/R AML的有效治疗手段。

To determine the efficacy and safety of selinexor combined with venetoclax(VEN)and azactitidine(AZA)for patients with relapsed and/or refractory acute myeloid leukemia(R/R AML).Twelve patients with R/R AML treated with selinexor plus VEN and AZA in the Affiliated Cancer Hospital of Zhengzhou University from May 2022 to May 2023 were included.Their clinical data were retrospectively analyzed.Among the 12 R/R AML patients,5(41.7%)achieved complete remission(CR),1(8.3%)achieved CR with incomplete hematological recovery,and 5(41.7%)achieved partial remission.The median time to reach CR was 28(16-59)days.The median PFS was 61(15-300)days.The main adverse event of the regimen was hematological toxicity.No chemotherapy-related deaths were observed.The combination of selinexor plus VEN and AZA is an effective treatment for R/R AML patients.